english.prescrire.org > Spotlight > 100 most recent > Tirzepatide (Mounjaro°) in type 2 diabetes

Spotlight

Every month, the subjects in Prescrire’s Spotlight.

100 most recent :  1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90

Tirzepatide (Mounjaro°) in type 2 diabetes

 Marketing Authorisations   A tirzepatide solution for subcutaneous injection has been authorised in the European Union for use in adults with type 2 diabetes, either as monotherapy when metformin use is considered inappropriate, or in combination with other glucose lowering-drugs. In these situations, is tirzepatide more effective than a GLP-1 agonist in preventing the complications of diabetes? And what are its adverse effects?
Full article available for download by subscribers (4 pages)

©Prescrire 1 November 2024

Source: "Tirzepatide (Mounjaro°) in type 2 diabetes" Prescrire Int 2024; 33 (264): 257-259. Subscribers only.

Enjoy full access to Prescrire International, and support independent information